Two Sigma Investments LP Sells 163,923 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Two Sigma Investments LP cut its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 60.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 109,419 shares of the company's stock after selling 163,923 shares during the period. Two Sigma Investments LP's holdings in Maravai LifeSciences were worth $596,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Performa Ltd US LLC increased its holdings in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock worth $27,000 after acquiring an additional 4,300 shares during the period. Farther Finance Advisors LLC grew its position in Maravai LifeSciences by 3,541.4% in the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock worth $56,000 after purchasing an additional 9,916 shares during the last quarter. Cibc World Markets Corp acquired a new stake in shares of Maravai LifeSciences in the fourth quarter valued at approximately $56,000. Atria Investments Inc bought a new stake in shares of Maravai LifeSciences during the fourth quarter valued at approximately $58,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Maravai LifeSciences during the fourth quarter worth approximately $78,000. Institutional investors own 50.25% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Robert W. Baird decreased their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Morgan Stanley decreased their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. Craig Hallum dropped their target price on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Stifel Nicolaus set a $5.00 target price on Maravai LifeSciences in a research report on Friday, March 21st. Finally, Bank of America lowered their price target on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Maravai LifeSciences currently has a consensus rating of "Hold" and an average price target of $6.64.

Maravai LifeSciences Trading Down 0.9%

Shares of Maravai LifeSciences stock traded down $0.02 on Thursday, reaching $2.26. 1,025,641 shares of the company were exchanged, compared to its average volume of 2,331,792. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $10.03. The firm has a market capitalization of $575.53 million, a price-to-earnings ratio of -1.38 and a beta of 0.25. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The stock has a fifty day moving average price of $2.06 and a 200-day moving average price of $3.58.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The company had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. The business's revenue was down 26.9% on a year-over-year basis. On average, analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.